Business Combination - Intangible Assets Acquired (Details) - Antares Pharma, Inc $ in Thousands |
May 24, 2022
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Estimated fair value of intangible assets acquired | $ 987,500 |
ATRS-1902 (IPR&D) | |
Business Acquisition [Line Items] | |
Indefinite-lived intangible assets acquired | 59,600 |
Auto Injector technology platform | |
Business Acquisition [Line Items] | |
Finite-lived intangible assets acquired | $ 372,900 |
Useful life (years) | 7 years |
XYOSTED proprietary product | |
Business Acquisition [Line Items] | |
Finite-lived intangible assets acquired | $ 277,400 |
Useful life (years) | 10 years |
TLANDO product rights | |
Business Acquisition [Line Items] | |
Finite-lived intangible assets acquired | $ 277,600 |
Useful life (years) | 10 years |